Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
2021; American Thoracic Society; Volume: 205; Issue: 5 Linguagem: Inglês
10.1164/rccm.202108-1986oc
ISSN1535-4970
AutoresDavid P. Nichols, Alex Paynter, Sonya L. Heltshe, Scott H. Donaldson, Carla A. Frederick, Steven D. Freedman, Daniel Gelfond, Lucas R. Hoffman, Andrea Kelly, Michael R. Narkewicz, Jessica E. Pittman, Félix Ratjen, Margaret Rosenfeld, Scott D. Sagel, Sarah Jane Schwarzenberg, Pradeep K. Singh, George M. Solomon, Michael S. Stalvey, John Clancy, Shannon Kirby, Jill M. Van Dalfsen, Margaret Kloster, Steven M. Rowe,
Tópico(s)Nematode management and characterization studies
ResumoThe cystic fibrosis (CF) modulator drug, elexacaftor/tezacaftor/ivacaftor (ETI), proved highly effective in controlled clinical trials for individuals with at least one F508del allele, which occurs in at least 85% of people with CF.
Referência(s)